Canaccord lowered the firm’s price target on Quanterix (QTRX) to $12 from $15 and keeps a Buy rating on the shares. The firm said they continue to view the stock as undervalued, although the challenging macroenvironment and upcoming merger with Akoya Biosciences (AKYA) adds uncertainty. The company posted a modest Q1 beat but that target decrease is due to lower near-term estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Reports Q1 2025 Results Amid Strategic Advances
- Cautious Hold Rating for Quanterix Amid Market Challenges and Strategic Uncertainties
- Quanterix Approves Cost-Reduction Plan Amidst Strategic Moves
- Quanterix reports Q1 EPS (53c) vs (29c) last year
- Quanterix cuts FY25 revenue view to $120M-$130M from $140M-$146M